N/A N=40 Venous Insufficiency and Neuromuscular Stimulation
Chronic Venous Disease · Venous Insufficiency · Deep Venous Obstruction
Primary: Percentage Change of Haemodynamic Flow — 34.8; 62.8; 9; 14.8 % change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 REVITIVE for the Treatment of Patients With Venous Insufficiency
Venous Insufficiency · Oedema · Varicose Veins
Primary: Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV — 102.4; -9.1 percentage change — p=0.001
Phase 2 N=72 Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
Venous Stasis Ulcers
Primary: Safety and Tolerability of Thymosin Beta 4 (Tβ4) Applied to Patients With Venous Stasis (VS) Ulcers for up to 84 Days — 24; 104 SAEs and AEs
N/A N=76 Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
Venous Leg Ulcer
Primary: Change From Baseline in Wound Perimeter — 29.36; 43.64 mm
N/A N=10 Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study
Coronary Heart Disease
Primary: Brachial Flow Velocity — 21.0 cm/sec
N/A N=18 Influence of Flat-knitted Compression Stockings Class I and II on Venous Malformations
Vascular Malformations · Vascular Malformation Peripheral · Venous Malformation
Primary: Volume Difference of Malformation to Baseline (no Compression) While Wearing Compression Stockings Class I and II Determined by MRI — 16.38; 23.7 ml
N/A N=10 Effect of Neuromuscular Calf Stimulation and Intermittent Pneumatic Compression on Lower Limb Venous Hemodynamics
Intermittent Pneumatic Compression
Primary: IPC(on) Peak Velocity Change From Baseline — 6.2 cm/s
N/A N=162 Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
May-Thurner Syndrome · Deep Vein Thrombosis · Chronic Venous Insufficiency
Primary: Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days — 157 Participants
N/A N=28 Predictive of Biomarkers of Healing in Chronic Venous Ulceration of the Lower Limb
Varicose Ulcer
Primary: Identification of Biomarkers Predictive of Ulcer Healing. — 9 Number of biomarkers
Phase 2 N=66 Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
Stasis Dermatitis
Primary: Percent Change From Baseline in Total Sign Score (TSS) at Week 6: In-person Assessment — -18.07; -32.44 Percent change — p=0.0299
N/A N=72 Preventing Seroma Formation After Stripping Saphenous Vein in Coronary Bypass
Coronary Bypass Graft Stenosis of Autologous Vein
Primary: Early Complications of Vascular Zone — 1; 4; 15; 5 participants — p=0.05
Phase 4 N=829 Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency
Chronic Venous Insufficiency
Primary: Mean Change (Reduction) From Baseline in Volume of Reference Leg at Week 16 — 1.13; 5.78 milliliters (mL) — p=0.531
N/A N=9 Intermittent Pneumatic Compression to Improve Revascularization Outcome
Peripheral Arterial Disease
Primary: Walking Endurance — -14; 35 Meters
N/A N=200 ABRE Clinical Study of the Abre Venous Self-expanding Stent System
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
N/A N=102 Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome
Acute Deep Vein Thrombosis
Primary: 2-year Change in Villalta Score — -1.5; -0.5 units on a scale — p=0.34
N/A N=12 Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS)
Post Thrombotic Syndrome · Deep Vein Thrombosis · Venous Stasis Syndrome
Primary: Median Optimal Electrical Stimulation Intensity Level for Largest Benefit in Relief of Symptoms — 32 mirco coulombs (0 to 50)
Phase 3 N=279 Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Varicose Veins
Primary: Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score) — 2.13; 4.63; 5.68; 4.87 units on a scale — p==0.0001
N/A N=381 Efficacy and Tolerability of Venoactive Drugs in Patients With Chronic Venous Diseases C4a&b in Real Clinical Practice.
Chronic Venous Diseases
Primary: The Mean Subcutaneous Adipose Tissue Thickness Changes (mm) Between the Visit 3 and Baseline by Ultrasound Examination. — 2.5 mm
N/A N=450 Early Venous Reflux Ablation Ulcer Trial
Venous Leg Ulcer
Primary: Time to Ulcer Healing From Date of Randomisation to Date of Healing up to 365 Days — 82; 56 days
N/A N=25 EU Post Market Clinical Follow-Up Study of the Venclose System for Saphenous Vein Incompetence
Chronic Venous Insufficiency
Primary: Vein Occlusion Rate — 29; 0; 0 limbs
N/A N=30 The Effect of Inelastic Compression System on Quality of Life in People With Chronic Venous Insufficiency
Chronic Venous Insufficiency
Primary: Change in the Quality of Life as Measured by CIVIQ-20 — 12.2 score on a scale
Phase 3 N=235 Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Varicose Veins
Primary: Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score) — -2.00; -5.34; -6.01; -5.06 units on a scale — p=<0.0001
N/A N=33 Vasculaire Compression System Increases Flow Velocity in the Femoral Vein
Venous Thrombosis
Primary: Change in Femoral Venous Peak Flow Velocity Compared to Resting Baseline — 18.9 cm/s — p=<0.0001
N/A N=28 Evaluation of a Dual Action Pneumatic Compression System: Tolerance and Comfort in Patients With Venous Leg Ulcers (VLUs)
Venous Leg Ulcer · Chronic Venous Insufficiency · Venous Stasis Ulcer
Primary: Number of Participants Who Agreed With Tolerance and Comfort Questionnaire Items After Using a Dual Action Pneumatic Compression Device — 12; 8; 9; 15 Participants
N/A N=20 A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices
Total Hip Arthroplasty
Primary: Peak Venous Velocity — 127.9; 155.7; 87.1; 86.8 cm/s
Phase 3 N=117 Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Great Saphenous Vein Incompetence · Visible Varicosities
Primary: Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score) — -0.80; -1.30; -1.11 score
N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
Phase 4 N=81 Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale
N/A N=170 BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease
May-Thurner Syndrome · Peripheral Vascular Disease · Venous Disease
Primary: Number of Participants With Primary Patency of the Venous Stent at 12 Months Post-Index Procedure — 128 Participants — p=0.0001
Phase 2 N=60 Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt
Varicose Veins
Primary: Patients With Circulating MCA Bubbles Present on MRI Who Had Signficant Clinical or Neurological Effects — 0 participants